We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+15.72%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$176M
AUM Growth
+$48.5M
(+38%)
Cap. Flow
-$44.1M
Cap. Flow
% of AUM
-25.07%
Top 10 Holdings %
Top 10 Hldgs %
75.9%
Holding
48
New
17
Increased
4
Reduced
8
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.6M |
| 2 |
United Therapeutics
UTHR
|
+$5.29M |
| 3 |
Addus HomeCare
ADUS
|
+$4.23M |
| 4 |
AbbVie
ABBV
|
+$3.32M |
| 5 |
UnitedHealth
UNH
|
+$2.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$11.8M |
| 2 |
GSK
GSK
|
+$8.99M |
| 3 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$8.74M |
| 4 |
AFAM
Almost Family Inc
AFAM
|
+$5.67M |
| 5 |
CFN
CAREFUSION CORPORATION
CFN
|
+$5.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.54% |
| 2 | Miscellaneous | 49.18% |
| 3 | Financials | 1.27% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
PUT
DELISTED
Celgene Corp
CELG
| $60.5M | 34.44% |
+525,000
| New | +$62.7M |
|
|
QTNT
2
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $19.1M | 10.87% |
28,091
-2,230
| -7% | -$1.41M |
|
|
PFNX
3
DELISTED
Pfenex Inc.
PFNX
| $10.4M | 5.93% |
653,393
+92,628
| +17% | +$1.02M |
|
|
4
Merck
MRK
$366B
| $8.34M | 4.74% |
+151,960
| New | +$8.6M |
|
5
PUT
Eli Lilly
LLY
$1.05T
| $7.26M | 4.13% |
+100,000
| New | +$7.12M |
|
6
PUT
AstraZeneca
AZN
$252B
| $6.84M | 3.89% |
+100,000
| New | +$6.95M |
|
|
7
United Therapeutics
UTHR
$22.1B
| $5.98M | 3.4% |
+34,700
| New | +$5.29M |
|
8
Cardinal Health
CAH
$54.6B
| $5.24M | 2.98% |
58,000
-4,100
| -7% | -$353K |
|
9
PUT
Johnson & Johnson
JNJ
$646B
| $5.03M | 2.86% |
+50,000
| New | +$5.08M |
|
|
DMK
10
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
| $4.65M | 2.65% |
16,857
+163
| +1% | +$70.4K |
|
|
11
Johnson & Johnson
JNJ
$646B
| $4.53M | 2.58% |
45,000
+5,000
| +13% | +$508K |
|
|
12
Addus HomeCare
ADUS
$2.16B
| $4.36M | 2.48% |
+189,466
| New | +$4.23M |
|
|
CERN
13
PUT
DELISTED
Cerner Corp
CERN
| $3.94M | 2.24% |
+53,800
| New | +$3.72M |
|
|
14
AbbVie
ABBV
$451B
| $3.22M | 1.83% |
+55,000
| New | +$3.32M |
|
|
15
UnitedHealth
UNH
$353B
| $3.13M | 1.78% |
+26,500
| New | +$2.94M |
|
|
PETX
16
DELISTED
Aratana Therapeutics, Inc.
PETX
| $2.86M | 1.63% |
178,550
-146,870
| -45% | -$2.61M |
|
|
EIGR
17
PUT
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $2.63M | 1.5% |
+308
| New | +$2.69M |
|
|
GTS
18
DELISTED
Triple-S Management Corporation
GTS
| $2.23M | 1.27% |
+118,144
| New | +$2.46M |
|
|
STML
19
DELISTED
Stemline Therapeutics, Inc.
STML
| $2.03M | 1.15% |
+140,000
| New | +$2.14M |
|
20
Heron Therapeutics
HRTX
$62M
| $2M | 1.14% |
+137,100
| New | +$1.55M |
|
|
FWP
21
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $1.91M | 1.09% |
9,636
-5,923
| -38% | -$961K |
|
|
AGRX
22
DELISTED
Agile Therapeutics
AGRX
| $1.89M | 1.08% |
102
-273
| -73% | -$4.78M |
|
|
BSTG
23
DELISTED
Biostage, Inc. Common Stock
BSTG
| $1.48M | 0.84% |
455,901
+320,639
| +237% | +$1.09M |
|
|
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.37M | 0.78% |
+46,677
| New | +$1.09M |
|
25
SCYNEXIS
SCYX
$53.6M
| $1.27M | 0.72% |
1,910
-247
| -11% | -$203K |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sio Capital Management held 48 positions worth $176M, up 38% from $127M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Sio Capital Management withdrew a net $44.1M in Q1 2015, closing 18 positions and reducing 8 holdings. Its most notable exit was Sanofi, an estimated $11.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Sio Capital Management opened a new position in Merck worth $8.34M.
- Sio Capital Management's largest Q1 2015 buy was Merck: 151,960 shares worth $8.34M.
- Sio Capital Management added most to Biostage, Inc. Common Stock in Q1 2015, an estimated $1.09M increase.
- Sio Capital Management's biggest Q1 2015 reduction was Agile Therapeutics, cutting an estimated $4.78M.
- Sio Capital Management fully exited Sanofi in Q1 2015, selling an estimated $11.8M.
- Sio Capital Management's ten largest holdings make up 76% of its $176M portfolio in Q1 2015.
- Sio Capital Management opened 17 new positions and closed 18 in Q1 2015.
- Sio Capital Management's portfolio value rose 38% quarter-over-quarter to $176M.
Based on Sio Capital Management's 13F filing for Q1 2015, filed 15 May 2015.